Technological projects portfolio
DACMMA
Cytotoxin coupled with an antibody to fight cancer
Investment: €469k
Scope: Healthcare
Scientific field(s): Biology and medicinal chemistry
Institution(s): Université Paris-Saclay - CNRS
Development: Start-up in progress/completed
USE CASES
Chemotherapy is often used to treat cancers. It relies on the use of cytotoxic molecules. These are powerful molecules but they often lead to harmful side effects due to their impact on healthy cells.
The coupling of cytotoxins with specific tumor antibodies (Antibody-Drug Conjugates, or ADC), allows for the development of more targeted and more effective treatments that improve patient survival rates.
The ADC market is rapidly expanding, however the cytotoxins that are commercially available remain very limited and have similar action modes, which increases the risk of resistance to these cytotoxins.
ADVANTAGES
The DACMMA technology responds to the medical need for new, powerful cytotoxins that present innovative modes of action. It is based on the development of highly cytotoxic molecules that are to be coupled with specific antibodies.
This approach enables the diversification of treatment mechanisms, the prevention of tumor resistance to medications and an increased effectiveness of the cytotoxins.
APPLICATIONS
DACMMA will be used to develop new ADCs that are used almost exclusively in cancer treatment protocols requiring chemotherapy: breast and ovarian cancer, lymphoma, leukemia, myeloma, lung cancer, prostate cancer, etc.
